- Home
- BZAI vs AGEN Comparison
BZAI vs AGEN Comparison
Compare BZAI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BZAI | AGEN |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 126.2M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | BZAI | AGEN |
|---|---|---|
| Price | $1.10 | $3.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.50 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.8M | 496.1K |
| Earning Date | 05-13-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $2,317.12 | $61.42 |
| Revenue Next Year | $250.65 | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.00 | $1.38 |
| 52 Week High | $6.76 | $7.34 |
Technical Indicators
Market Signals| Indicator | BZAI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 57.34 |
| Support Level | $1.04 | $2.91 |
| Resistance Level | $1.57 | $4.66 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 45.45 | 64.29 |
Price Performance
Historical ComparisonAbout BZAI Blaize Holdings Inc.
Blaize Holdings Inc provides a customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).